Under one in 10 patients that would benefit from weight-loss injections such as Wegovy can access them, warns the global health agency as it issues its inaugural recommendations on the drugs.
Considering over a billion individuals worldwide now obese, it is calling for broader and more equitable access to this class of drugs.
According to projections, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"Our new guidelines affirms that excess weight is a long-term condition that can be treated with thorough and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are key hurdles to universal access to the jabs that can assist patients in reducing significant weight, says the body.
Skinny Jab Shortage
Despite the present most optimistic case, the manufacturing of these medications would only suffice for about 100 million people – less than 10% of eligible patients, according to the health organization.
The advice urges nations and manufacturers to widen availability, by measures including patent sharing.
Exclusive production rights on a key compound – the core component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Jabs Work
The injections imitate a natural hormone to delay gastric emptying, reduce hunger and enhance the sense of being full so people reduce food intake.
Patients typically start to lose weight after several weeks of beginning the weekly injections.
Studies indicates people may regain a significant portion after a year of discontinuing the treatment, because their usual hunger come back.
Being overweight or obese raises your chance for experiencing medical conditions, like type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity affects people in every country and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.
